Search Results

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that company management will present at the Citizens JMP Life Sciences Conference taking place in New York, NY, from May 13 – 14, 2024.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, provided a corporate update and reported financial results for the three months ended March 31, 2024.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, hosted a virtual Key Opinion Leader event discussing the significant unmet medical need in the prevention of surgical site infections.

PolyPid Ltd. announced that it will host a virtual Key Opinion Leader event on Monday, June 17, 2024, at 10:00 AM ET, to discuss the significant unmet medical need in surgical site infections and provide an update on the Company’s ongoing D-PLEX100 Phase 3 trial.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that it will report its first quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, May 8, 2024.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, announced that Company management will participate in a fireside chat at the Barclays 26th Annual Global Healthcare Conference taking place in Miami Beach, FL, March 12 – 14, 2024.

PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has enrolled and randomized the 100th patient in its ongoing SHIELD II Phase 3 trial for D-PLEX100 for the prevention of surgical site infections in patients undergoing abdominal colorectal surgery with large incisions.